Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2Phase NA 1Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1061Neoplasms 887Prostatic Neoplasms 513Lung Neoplasms 426Colorectal Neoplasms 360Motor Activity 226Head and Neck Neoplasms 195Uterine Cervical Neoplasms 194Carcinoma, Non-Small-Cell Lung 182Brain Neoplasms 176Pancreatic Neoplasms 162Ovarian Neoplasms 143Colonic Neoplasms 140Carcinoma, Hepatocellular 137Anxiety Disorders 125Rectal Neoplasms 119Hematologic Neoplasms 116Multiple Myeloma 109Stomach Neoplasms 105Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Melanoma 93Depression 93Pain 89Urinary Bladder Neoplasms 88Glioblastoma 87Endometrial Neoplasms 87Disease 85Lymphoma 84Sarcoma 78

Interventions

Valganciclovir 1Valacyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Cytomegalovirus Infections × 1 year × Clear all
NCT07294547 2025-12-19

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

National Taiwan University Hospital

Phase NA Recruiting
80 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡